Synpromics Blog Synpromics joins ARM and the BIA at the Houses of Parliament to launch their inaugural joint report

Synpromics was proud to be featured at the launch of the inaugural joint report from the Alliance for Regenerative Medicine (ARM) and the UK BioIndustry Association (BIA) entitled 'Leading Innovation: The UK's ATMP Landscape'. Nick Higgins attended the launch at the Houses of Parliament where he presented a poster detailing our recent progress in gene expression using our PromPT® technology platform and our successful collaboration with uniQure.Nick Higgins presents the Synpromics posterThe ARM/BIA country specific report details the UK's position as a leading source of innovation in the research and development of advanced therapy medicinal products (ATMPs) in Europe and globally. It looks into the current clinical and commercial landscape of ATMP developers in the country, with a particular focus on the UK's history of ATMP support and the positive role of government agencies. ATMPs are a fast-growing part of the UK economy and the report also demonstrates how the UK is working to address challenges facing ATMP developers. The full report can be viewed here.Synpromics was chosen to feature in the report as an example of the progress UK-based companies are making in the development of novel cell and gene medicines. Our PromPT technology is used to create novel promoters that satisfy a discrete set of specifications such as the size of the promoter; the selectivity and strength of the promoter; and whether the promoter is constitutively expressed in the target cell type or regulated/inducible in the cell. These new promoters are then used to drive efficient, and finely tuned, gene expression so that the therapeutic effect is safe, directed, and durable and optimized for the disease being treated.Our recent collaboration with uniQure aimed to develop highly potent, liver selective promoters for gene therapy applications. uniQure recognized that a collaboration with Synpromics would allow them to improve the safety and efficacy profile of their clinical programs delivering gene payloads to the liver. The collaboration created promoters that were 50 times more active than the industry standard and the promoter is now being incorporated into potential treatments for hemophilia A and Fabry disease. The collaboration continues to flourish, and we look forward to working together to further the development of gene therapies. Click here to view our poster from the launch.The report launch also featured an interesting discussion between Steve Bates, Chief Executive, Bioindustry Association; Janet Lynch Lambert, Chief Executive, Alliance for Regenerative Medicine; Keith Thompson, Cell and Gene Therapy Catapult and Henny Braund, CEO, Anthony Nolan.This joint report from ARM and the BIA is a great example of how UK companies are contributing to the development of ATMPs and leading the global drive to understand and treat some of the world's previously untreatable diseases.Tweet